Pub. Date : 2017 Aug
PMID : 28700521
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers. | Sirolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 2 | Sirolimus is primarily metabolized by cytochrome CYP3A4 and CYP3A5. | Sirolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 3 | This study aimed to clarify the effect of CYP3A genetic polymorphisms, including the CYP3A4*1G and CYP3A5*3 polymorphisms, on the pharmacokinetics of sirolimus. | Sirolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 4 | This study aimed to clarify the effect of CYP3A genetic polymorphisms, including the CYP3A4*1G and CYP3A5*3 polymorphisms, on the pharmacokinetics of sirolimus. | Sirolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 5 | CONCLUSIONS: CYP3A4 and CYP3A5 genetic polymorphisms are important factors affecting pharmacokinetic parameters of sirolimus. | Sirolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |
| 6 | Our data support the monitoring of blood sirolimus concentrations, especially in CYP3A5*1 and CYP3A4*1 G carriers, to ensure accurate dosing in the clinical setting. | Sirolimus | cytochrome P450 family 3 subfamily A member 4 | Homo sapiens |